Treatment-resistant depression appears frequently in discussions of ketamine therapy, though the strength of the supporting evidence differs considerably from indication to indication and it is worth being precise about where this one sits. The current position is that ketamine use for treatment-resistant depression is best described as strongest evidence, and its regulatory status is esketamine fda-approved; iv ketamine off-label. This page covers the mechanism as currently understood, the shape of the trial evidence, who the treatment is realistically appropriate for, how a course is structured, what it costs, and the questions worth putting to a clinician before starting.
Remote consultation paired with on-site administration is a sensible hybrid, and several programmes now structure themselves that way for travelling patients. That holds in the United States as it does everywhere: commercial insurance seldom reimburses off-label intravenous administration, though the associated psychiatric evaluation is sometimes billable and worth asking about specifically. Anyone comparing the United States programmes will find this decisive: because esketamine carries a Risk Evaluation and Mitigation Strategy, it can only be administered at certified centres with at least two hours of post-dose observation. In the United States the same rule applies: someone who has not yet tried a first-line treatment is usually better served starting there, where the evidence is stronger, the cost lower and the risk profile better understood. Resuscitation equipment on site and a clinician credentialed to manage sedation are the structural elements that make the treatment defensible outside a research setting.
What the research says about ketamine and Treatment-resistant depression
Randomised controlled trials have reported rapid reductions in depressive symptom scores after subanaesthetic infusions, often visible within hours to days rather than the weeks conventional antidepressants require. For anyone weighing options in the United States, antagonism at the N-methyl-D-aspartate receptor appears to trigger a downstream cascade involving brain-derived neurotrophic factor and increased synaptic connectivity in mood-regulating regions. Coordination with an existing prescriber is a marker of considered practice, even though it slows the path to a first appointment. Patients researching the United States providers run into this constantly.
What follows applies to the United States and to every other market, and it is the part worth reading slowly. Screening is where a careful programme distinguishes itself, and it happens before anyone discusses scheduling. A thorough intake covers cardiovascular history, because of the blood pressure response; personal and family history of psychosis or bipolar disorder, because of the risk of precipitating an episode; hepatic function, because the liver metabolises the drug; substance use history; current medications and their interactions; and pregnancy status. It should also establish what has already been tried and at what dose, since the term treatment-resistant carries a specific meaning that only applies after adequate trials of at least two antidepressants. A consultation that skips most of this and moves quickly to a package price is telling you something about how the clinic is run.
Integration is the term the field uses for the work of making sense of what happened, and it is the element most likely to be missing from a purely procedural clinic. The neuroplasticity hypothesis implies that the days following a session may be unusually receptive to therapeutic change, which suggests that pairing sessions with structured psychological support is not an upsell but a plausible way to use the window. Programmes vary enormously in how seriously they take this: some employ therapists and build integration sessions into the protocol, others hand over a worksheet, and some do nothing at all. Asking directly what integration support is included, and whether it costs extra, separates the two models quickly.
How a course is structured for this indication
Weight-based dosing in the region of 0.5 milligrams per kilogram over roughly forty minutes is the convention, though clinics vary in whether they adjust it between sessions. Nothing about the United States changes that. The open question in the field is durability, which is why the maintenance conversation belongs in the first consultation rather than the seventh week. The United States listings on this page are organised so that this is checkable rather than assumed. The trial protocols that produced the evidence base were run in monitored medical environments, and the monitoring was part of what made them safe rather than an accessory to it. Preparation before the first session matters for the same reason: people who know in advance what the dissociative period feels like generally find it far less alarming.
The background that makes the United States listings interpretable is this. Ketamine has been in continuous clinical use since the United States Food and Drug Administration approved it as a general anaesthetic in 1970, which makes it one of the better characterised drugs in modern medicine from a safety standpoint. What is new is not the molecule but the dose and the intention behind it. Anaesthetic dosing renders a person unconscious for surgery; the subanaesthetic dosing used in mood work is a fraction of that, typically calculated at around 0.5 milligrams per kilogram of body weight delivered slowly over roughly forty minutes. At that level the person stays awake, breathing on their own, able to speak and to signal discomfort. The half century of anaesthetic safety data is genuinely reassuring about the drug itself, and it is also not the same thing as long-term safety data for repeated low-dose psychiatric use, which is a younger and thinner body of evidence.
Who is realistically a candidate for treatment of Treatment-resistant depression
Read against the United States market, a consultation that moves quickly from hello to a package price has skipped the assessment that determines whether treatment is appropriate at all. A history of psychosis or a bipolar diagnosis changes the risk calculation substantially, which is why a thorough intake asks about family psychiatric history and not only personal history. Esketamine, sold as Spravato, holds FDA approval for treatment-resistant depression in adults alongside an oral antidepressant, which puts it in a different regulatory category from generic infusions. It is worth carrying that into every conversation with a the United States provider.
Every the United States programme is operating inside the same clinical framework, which runs as follows. There is a specific population for whom this conversation is most relevant, and it is narrower than the advertising implies. The trial evidence concentrates on adults with major depressive disorder who have not responded adequately to at least two antidepressant trials at appropriate doses and durations. If someone has never tried a first-line treatment, the reasonable clinical answer is usually to start there, because the evidence is stronger, the cost is lower and the risk profile is better understood. A clinic that agrees to treat anyone who asks, without reference to what has been tried, has replaced clinical judgement with a booking system.
Risks, side effects and screening
The infusion can be slowed or stopped if someone becomes distressed, and knowing that in advance is itself a meaningful part of preparation. That is as true in the United States as anywhere else in the country. Screening should cover cardiovascular history, personal and family history of psychosis or bipolar disorder, hepatic function, substance use history and current medications. It is the first thing to establish about any the United States programme. Applied to the United States, the point is this: continuous monitoring of blood pressure, heart rate and oxygen saturation is the baseline, because subanaesthetic dosing reliably produces a modest rise in the first two.
Cost is the constraint that decides the matter for a large share of people, and the numbers are rarely posted plainly. A single intravenous infusion in the United States commonly falls somewhere between four hundred and eight hundred dollars, which puts a six-session induction in the range of roughly two and a half to five thousand dollars before any maintenance. Commercial insurance seldom reimburses off-label intravenous administration, though the associated psychiatric evaluation is sometimes billable. Esketamine is a different story, since an approved indication makes coverage plausible, subject to prior authorisation and documented failure of prior treatments. Before committing to anything, it is worth asking for the total cost of the induction course, the cost of a maintenance session, whether the consultation is billed separately, and what happens financially if treatment is stopped partway through.
What treatment costs and what insurance does
A single infusion in the United States commonly falls between four hundred and eight hundred dollars, putting a six-session induction somewhere near two and a half to five thousand. For anyone whose decision turns on cost, asking whether a provider offers esketamine as well as intravenous administration is among the higher-value questions available. Telehealth has a legitimate role here for consultation, screening, follow-up and integration therapy, and it materially improves access for people far from a metropolitan clinic.
Start with what is actually established
The practical difference is that esketamine is approved and more often insurable but less flexible, while intravenous ketamine is off-label, usually self-funded and more adjustable. The subanaesthetic dose used in this work is a fraction of the surgical dose, which is why the person stays awake, breathing independently and able to communicate. Applied to the United States, the point is this: the useful test for a remote programme is which components happen remotely and which require a monitored setting, and whether the answer is clear. Headache, dizziness and several hours of grogginess afterwards are ordinary, and driving is prohibited for the remainder of the day without exception. The difficulty facing someone comparing options in the United States is not a shortage of information but an excess of the promotional kind.
Set aside the United States for a moment, because the general position comes first. Side effects during a session are common, usually transient, and worth knowing about in advance rather than discovering in the chair. Dissociation is the one people ask about most: a sense of distance from the body, altered perception of time, sometimes visual distortion. For most people it peaks partway through the infusion and resolves within twenty to thirty minutes of the drip finishing. Nausea is frequent enough that many clinics give an antiemetic pre-emptively. Blood pressure and heart rate typically rise modestly during administration, which is the reason continuous monitoring is standard and the reason uncontrolled hypertension is treated as a serious caution. Headache, dizziness and a period of grogginess afterwards are ordinary. Driving is prohibited for the rest of the day without exception.
Ketamine is a Schedule III controlled substance, which formally recognises a potential for misuse and shapes how responsible programmes are structured. It is worth carrying that into every conversation with a the United States provider. That holds in the United States as it does everywhere: using remote care to mail a dissociative anaesthetic to an unmonitored patient is a different proposition from using it for the consultation, and the distinction is worth insisting on. The population the trial evidence covers is narrower than the advertising implies, concentrating on adults who have not responded to at least two adequate antidepressant trials. Patients researching the United States providers run into this constantly. Nausea is common enough that many programmes give an antiemetic pre-emptively rather than waiting to see. That is as true in the United States as anywhere else in the country. Anyone comparing the United States programmes will find this decisive: a programme should be able to say plainly who is in the building during a session, what their credential is, and what the plan is if a person becomes acutely distressed.
Making a decision about Treatment-resistant depression treatment
Distance is a clinical variable in a treatment requiring six visits in three weeks, which is exactly why remote components deserve serious consideration rather than dismissal. It is the first thing to establish about any the United States programme. The mechanism matters practically because it implies the days after a session may be unusually receptive to therapeutic work. For anyone weighing options in the United States, approval for esketamine extends to depressive symptoms in adults with major depressive disorder and acute suicidal ideation, a narrow and specific indication rather than a general one. The information gap in the United States is not about whether ketamine treatment exists locally but about how to tell two local programmes apart. In the United States the same rule applies: the relevant question about a provider is not only whether they are licensed but whether their training covers both the psychiatric assessment and the physiological monitoring.
The point of laying all this out is not to argue for or against treatment. It is to make sure that whichever way the decision goes, it is made with the real numbers and the real caveats rather than the marketing version.
This page is general information, not medical advice, and no directory can assess whether a treatment is appropriate for an individual. Ketamine is a controlled substance with genuine risks, and its use for mood disorders is off-label apart from esketamine, which holds FDA approval for treatment-resistant depression under a restricted programme. Decisions about treatment should be made with a qualified clinician who knows your full history. If you are in crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988 in the United States, or go to your nearest emergency department.